![Edward Samuel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Edward Samuel
Director Técnico/Científico/I+D en ACHILLES THERAPEUTICS PLC .
Perfil
Edward Samuel is currently working as the SVP-Technical Operations at Achilles Therapeutics Plc since 2022.
Previously, he worked as the Director-Manufacturing at Cognate BioServices, Inc. from 2015 to 2017 and as the Manager-Cell Therapy Operations at Orchard Therapeutics Plc in 2017.
Dr. Samuel holds a doctorate degree from University College London and a graduate degree from King's College London.
Cargos activos de Edward Samuel
Empresas | Cargo | Inicio |
---|---|---|
ACHILLES THERAPEUTICS PLC | Director Técnico/Científico/I+D | 01/02/2022 |
Antiguos cargos conocidos de Edward Samuel.
Empresas | Cargo | Fin |
---|---|---|
ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | 01/12/2017 |
Cognate BioServices, Inc.
![]() Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Corporate Officer/Principal | 01/05/2017 |
Formación de Edward Samuel.
University College London | Doctorate Degree |
King's College London | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ACHILLES THERAPEUTICS PLC | Health Technology |
Empresas privadas | 2 |
---|---|
Orchard Therapeutics Plc
![]() Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Cognate BioServices, Inc.
![]() Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Health Technology |
- Bolsa de valores
- Insiders
- Edward Samuel